Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00835770
Registration number
NCT00835770
Ethics application status
Date submitted
2/02/2009
Date registered
4/02/2009
Date last updated
31/12/2020
Titles & IDs
Public title
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
Query!
Scientific title
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Query!
Secondary ID [1]
0
0
2008-004753-14
Query!
Secondary ID [2]
0
0
109MS303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ENDORSE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsing-Remitting Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - dimethyl fumarate
Treatment: Drugs - Placebo
Experimental: BG00012 plus placebo - In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
Experimental: BG00012 - In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
Treatment: Drugs: dimethyl fumarate
BG00012 capsules
Treatment: Drugs: Placebo
Capsules taken to maintain the blind in the 240 mg BID treatment group.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Query!
Assessment method [1]
0
0
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Query!
Timepoint [1]
0
0
Day 1 up to Week 561
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Had Relapses
Query!
Assessment method [1]
0
0
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.
Query!
Timepoint [1]
0
0
Day 1 up to Week 384
Query!
Secondary outcome [2]
0
0
Annualized Relapse Rate (ARR)
Query!
Assessment method [2]
0
0
The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.
Query!
Timepoint [2]
0
0
Day 1 up to Week 384
Query!
Secondary outcome [3]
0
0
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384
Query!
Assessment method [3]
0
0
EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS =1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.
Query!
Timepoint [3]
0
0
Baseline, Week 384
Query!
Secondary outcome [4]
0
0
Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [4]
0
0
The Gd-enhancing lesions was evaluated using MRI technique.
Query!
Timepoint [4]
0
0
Baseline up to Week 288
Query!
Secondary outcome [5]
0
0
Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [5]
0
0
The Gd-enhancing lesions was evaluated using MRI technique.
Query!
Timepoint [5]
0
0
Baseline up to Week 288
Query!
Secondary outcome [6]
0
0
Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [6]
0
0
The T2 lesions was evaluated using MRI technique.
Query!
Timepoint [6]
0
0
Baseline up to Week 288
Query!
Secondary outcome [7]
0
0
Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [7]
0
0
The T2 lesions was evaluated using MRI technique.
Query!
Timepoint [7]
0
0
Baseline up to Week 288
Query!
Secondary outcome [8]
0
0
Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [8]
0
0
The T1 hypointense lesions was evaluated using MRI technique.
Query!
Timepoint [8]
0
0
Baseline up to Week 288
Query!
Secondary outcome [9]
0
0
Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [9]
0
0
The T1 hypointense lesions was evaluated using MRI technique.
Query!
Timepoint [9]
0
0
Baseline up to Week 288
Query!
Secondary outcome [10]
0
0
Percent Change From Baseline in Brain Atrophy
Query!
Assessment method [10]
0
0
Brain atrophy was measured using magnetic resonance imaging (MRI) technique.
Query!
Timepoint [10]
0
0
Baseline up to Week 288
Query!
Secondary outcome [11]
0
0
Percent Change From Baseline in Magnetization Transfer Ratio (MTR)
Query!
Assessment method [11]
0
0
Magnetization Transfer Ratio (MTR) was measured using MRI technique.
Query!
Timepoint [11]
0
0
Baseline up to Week 288
Query!
Secondary outcome [12]
0
0
Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384
Query!
Assessment method [12]
0
0
The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.
Query!
Timepoint [12]
0
0
Baseline, Week 384
Query!
Secondary outcome [13]
0
0
Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384
Query!
Assessment method [13]
0
0
The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) "no problems", (2) "some problems", or (3) "severe problems". A positive change from baseline indicates improvement.
Query!
Timepoint [13]
0
0
Baseline, Week 384
Query!
Secondary outcome [14]
0
0
Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384
Query!
Assessment method [14]
0
0
The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents "worst imaginable health state" and 100 represents "best imaginable health state". A positive change from baseline indicates improvement.
Query!
Timepoint [14]
0
0
Baseline, Week 384
Query!
Secondary outcome [15]
0
0
Change From Baseline in Visual Function Test Scores at Week 384
Query!
Assessment method [15]
0
0
Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.
Query!
Timepoint [15]
0
0
Baseline, Week 384
Query!
Eligibility
Key inclusion criteria
Key
-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).
Key
Query!
Minimum age
19
Years
Query!
Query!
Maximum age
58
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any significant change in medical history from 109MS301 or 109MS302 that would have excluded subject's participation from their previous study.
* Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE or due to reasons other than protocol-defined relapse/disability progression.
* Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability progression or relapses and did not follow the modified visit schedule up to Week 96.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/02/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/11/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1736
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Research Site - New Lambton Heights
Query!
Recruitment hospital [3]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [4]
0
0
Research Site - Box Hill
Query!
Recruitment hospital [5]
0
0
Research Site - Chatswood
Query!
Recruitment hospital [6]
0
0
Research Site - Fitzroy
Query!
Recruitment hospital [7]
0
0
Research Site - Geelong
Query!
Recruitment hospital [8]
0
0
Research Site - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [3]
0
0
3084 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [5]
0
0
2067 - Chatswood
Query!
Recruitment postcode(s) [6]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [7]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [8]
0
0
2000 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Rhode Island
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Virginia
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Washington
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Wisconsin
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Graz
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Linz
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Vienna
Query!
Country [32]
0
0
Belarus
Query!
State/province [32]
0
0
Gomel
Query!
Country [33]
0
0
Belarus
Query!
State/province [33]
0
0
Vitebsk
Query!
Country [34]
0
0
Belarus
Query!
State/province [34]
0
0
Minsk
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Antwerpen
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Brugge
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Brussels
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Charleroi
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Damme
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Diepenbeek
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Hechtel-Eksel
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Leuven
Query!
Country [43]
0
0
Belgium
Query!
State/province [43]
0
0
Lodelinsart
Query!
Country [44]
0
0
Belgium
Query!
State/province [44]
0
0
Sint-Truiden
Query!
Country [45]
0
0
Bosnia and Herzegovina
Query!
State/province [45]
0
0
Tuzla
Query!
Country [46]
0
0
Bulgaria
Query!
State/province [46]
0
0
Ruse
Query!
Country [47]
0
0
Bulgaria
Query!
State/province [47]
0
0
Sofia
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Quebec
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Edmonton
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
London
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Montreal
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Nova Scotia
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Ottawa
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Regina
Query!
Country [55]
0
0
Croatia
Query!
State/province [55]
0
0
Zagreb
Query!
Country [56]
0
0
Czechia
Query!
State/province [56]
0
0
Brno
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Jihlava
Query!
Country [58]
0
0
Czechia
Query!
State/province [58]
0
0
Moravska Ostrava
Query!
Country [59]
0
0
Czechia
Query!
State/province [59]
0
0
Olomouc
Query!
Country [60]
0
0
Czechia
Query!
State/province [60]
0
0
Opava
Query!
Country [61]
0
0
Czechia
Query!
State/province [61]
0
0
Ostrava - Vítkovice
Query!
Country [62]
0
0
Czechia
Query!
State/province [62]
0
0
Prague
Query!
Country [63]
0
0
Czechia
Query!
State/province [63]
0
0
Teplice
Query!
Country [64]
0
0
Estonia
Query!
State/province [64]
0
0
Parnu
Query!
Country [65]
0
0
Estonia
Query!
State/province [65]
0
0
Tallinn
Query!
Country [66]
0
0
Estonia
Query!
State/province [66]
0
0
Tartu
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Amiens
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Caen
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Clermont-Ferrand
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Dijon
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Lille
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Lyon
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Marseille
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Montpellier
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Nancy
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Nice
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Paris
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Rennes
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Strasbourg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Bavaria
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Ibbenbueren
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Bayreuth
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Berlin
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Bochum
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Dresden
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Dusseldorf
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Erbach
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Erlangen
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Essen
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Halle
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Hamburg
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Hannover
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Koeln
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Leipzig
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Magdeburg
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Marburg
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Minden
Query!
Country [98]
0
0
Germany
Query!
State/province [98]
0
0
Munich (München)
Query!
Country [99]
0
0
Germany
Query!
State/province [99]
0
0
Münster
Query!
Country [100]
0
0
Germany
Query!
State/province [100]
0
0
Osnabrück
Query!
Country [101]
0
0
Germany
Query!
State/province [101]
0
0
Regensburg
Query!
Country [102]
0
0
Germany
Query!
State/province [102]
0
0
Westerstede
Query!
Country [103]
0
0
Greece
Query!
State/province [103]
0
0
Athens
Query!
Country [104]
0
0
Greece
Query!
State/province [104]
0
0
Thessaloniki
Query!
Country [105]
0
0
India
Query!
State/province [105]
0
0
Ahmedabad
Query!
Country [106]
0
0
India
Query!
State/province [106]
0
0
Bangalore
Query!
Country [107]
0
0
India
Query!
State/province [107]
0
0
Chandigarh
Query!
Country [108]
0
0
India
Query!
State/province [108]
0
0
Hyderabad
Query!
Country [109]
0
0
India
Query!
State/province [109]
0
0
Kolkata
Query!
Country [110]
0
0
India
Query!
State/province [110]
0
0
Ludhiana
Query!
Country [111]
0
0
India
Query!
State/province [111]
0
0
Mangalore
Query!
Country [112]
0
0
India
Query!
State/province [112]
0
0
Mumbai
Query!
Country [113]
0
0
India
Query!
State/province [113]
0
0
New Delhi
Query!
Country [114]
0
0
India
Query!
State/province [114]
0
0
Pune
Query!
Country [115]
0
0
Ireland
Query!
State/province [115]
0
0
Dublin
Query!
Country [116]
0
0
Israel
Query!
State/province [116]
0
0
Ashkelon
Query!
Country [117]
0
0
Israel
Query!
State/province [117]
0
0
Jerusalem
Query!
Country [118]
0
0
Israel
Query!
State/province [118]
0
0
Safed
Query!
Country [119]
0
0
Italy
Query!
State/province [119]
0
0
Roma
Query!
Country [120]
0
0
Latvia
Query!
State/province [120]
0
0
Riga
Query!
Country [121]
0
0
Mexico
Query!
State/province [121]
0
0
Guadalajara
Query!
Country [122]
0
0
Mexico
Query!
State/province [122]
0
0
Mexico
Query!
Country [123]
0
0
Mexico
Query!
State/province [123]
0
0
Morelia
Query!
Country [124]
0
0
Mexico
Query!
State/province [124]
0
0
San Luis Potosi
Query!
Country [125]
0
0
Moldova, Republic of
Query!
State/province [125]
0
0
Chisinau
Query!
Country [126]
0
0
Netherlands
Query!
State/province [126]
0
0
Breda
Query!
Country [127]
0
0
Netherlands
Query!
State/province [127]
0
0
Geleen
Query!
Country [128]
0
0
New Zealand
Query!
State/province [128]
0
0
Auckland
Query!
Country [129]
0
0
New Zealand
Query!
State/province [129]
0
0
Christchurch
Query!
Country [130]
0
0
New Zealand
Query!
State/province [130]
0
0
Hamilton
Query!
Country [131]
0
0
North Macedonia
Query!
State/province [131]
0
0
Skopje
Query!
Country [132]
0
0
Poland
Query!
State/province [132]
0
0
Bialystok
Query!
Country [133]
0
0
Poland
Query!
State/province [133]
0
0
Gdansk
Query!
Country [134]
0
0
Poland
Query!
State/province [134]
0
0
Katowice
Query!
Country [135]
0
0
Poland
Query!
State/province [135]
0
0
Krakow
Query!
Country [136]
0
0
Poland
Query!
State/province [136]
0
0
Lublin
Query!
Country [137]
0
0
Poland
Query!
State/province [137]
0
0
Lódz
Query!
Country [138]
0
0
Poland
Query!
State/province [138]
0
0
Olsztyn
Query!
Country [139]
0
0
Poland
Query!
State/province [139]
0
0
Plewiska
Query!
Country [140]
0
0
Poland
Query!
State/province [140]
0
0
Poznan
Query!
Country [141]
0
0
Poland
Query!
State/province [141]
0
0
Szczecin
Query!
Country [142]
0
0
Poland
Query!
State/province [142]
0
0
Warszawa
Query!
Country [143]
0
0
Poland
Query!
State/province [143]
0
0
Wroclaw
Query!
Country [144]
0
0
Puerto Rico
Query!
State/province [144]
0
0
Guaynabo
Query!
Country [145]
0
0
Romania
Query!
State/province [145]
0
0
Bucuresti
Query!
Country [146]
0
0
Romania
Query!
State/province [146]
0
0
Cluj-Napoca
Query!
Country [147]
0
0
Romania
Query!
State/province [147]
0
0
Timisoara
Query!
Country [148]
0
0
Romania
Query!
State/province [148]
0
0
Târgu Mures
Query!
Country [149]
0
0
Serbia
Query!
State/province [149]
0
0
Belgrade
Query!
Country [150]
0
0
Serbia
Query!
State/province [150]
0
0
Kragujevac
Query!
Country [151]
0
0
Serbia
Query!
State/province [151]
0
0
Nis
Query!
Country [152]
0
0
Serbia
Query!
State/province [152]
0
0
Novi Sad
Query!
Country [153]
0
0
Slovakia
Query!
State/province [153]
0
0
Bratislava
Query!
Country [154]
0
0
Slovakia
Query!
State/province [154]
0
0
Martin
Query!
Country [155]
0
0
South Africa
Query!
State/province [155]
0
0
Cape Town
Query!
Country [156]
0
0
South Africa
Query!
State/province [156]
0
0
Durban
Query!
Country [157]
0
0
Spain
Query!
State/province [157]
0
0
Barcelona
Query!
Country [158]
0
0
Spain
Query!
State/province [158]
0
0
Córdoba
Query!
Country [159]
0
0
Spain
Query!
State/province [159]
0
0
Madrid
Query!
Country [160]
0
0
Spain
Query!
State/province [160]
0
0
Malaga
Query!
Country [161]
0
0
Spain
Query!
State/province [161]
0
0
Sevilla
Query!
Country [162]
0
0
Switzerland
Query!
State/province [162]
0
0
Basel
Query!
Country [163]
0
0
Switzerland
Query!
State/province [163]
0
0
St. Gallen
Query!
Country [164]
0
0
Switzerland
Query!
State/province [164]
0
0
Zurich
Query!
Country [165]
0
0
Ukraine
Query!
State/province [165]
0
0
Ivano-Frankivsk
Query!
Country [166]
0
0
Ukraine
Query!
State/province [166]
0
0
Kharkiv
Query!
Country [167]
0
0
Ukraine
Query!
State/province [167]
0
0
Kyiv
Query!
Country [168]
0
0
Ukraine
Query!
State/province [168]
0
0
Lviv
Query!
Country [169]
0
0
Ukraine
Query!
State/province [169]
0
0
Odessa
Query!
Country [170]
0
0
Ukraine
Query!
State/province [170]
0
0
Poltava
Query!
Country [171]
0
0
Ukraine
Query!
State/province [171]
0
0
Vinnytsia
Query!
Country [172]
0
0
Ukraine
Query!
State/province [172]
0
0
Zaporizhzhia
Query!
Country [173]
0
0
United Kingdom
Query!
State/province [173]
0
0
London
Query!
Country [174]
0
0
United Kingdom
Query!
State/province [174]
0
0
Newcastle upon Tyne
Query!
Country [175]
0
0
United Kingdom
Query!
State/province [175]
0
0
Oxford
Query!
Country [176]
0
0
United Kingdom
Query!
State/province [176]
0
0
Sheffield
Query!
Country [177]
0
0
United Kingdom
Query!
State/province [177]
0
0
Stoke on Trent
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Biogen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00835770
Query!
Trial related presentations / publications
Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Chen C, Parks B, Miller C. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020 May 12;13:1756286420915005. doi: 10.1177/1756286420915005. eCollection 2020. Erratum In: Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420968357. doi: 10.1177/1756286420968357. Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27. Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther. 2016 Jun;5(1):45-57. doi: 10.1007/s40120-016-0042-8. Epub 2016 Mar 1.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Biogen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/70/NCT00835770/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/70/NCT00835770/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00835770
Download to PDF